{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:03:46Z","timestamp":1781625826317,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40262-026-01642-4","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:18:36Z","timestamp":1777709916000},"page":"915-927","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating Bayesian Vancomycin Dosage Adjustment in Neonates: A Simulation-Based Virtual TDM Study"],"prefix":"10.1007","volume":"65","author":[{"given":"Anne","family":"Ravix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Thoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Cathignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Thoueille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catia","family":"Marzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Giannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Csajka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6419-9317","authenticated-orcid":false,"given":"Monia","family":"Guidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"1642_CR1","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, LeJ LTP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America. Pediatr Am J Health Syst Pharm. 2020;77:835\u201364.","journal-title":"Pediatr Am J Health Syst Pharm"},{"key":"1642_CR2","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s40262-018-0727-5","volume":"58","author":"PJ Colin","year":"2019","unstructured":"Colin PJ, Allegaert K, Thomson AH, et al. Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations. Clin Pharmacokinet. 2019;58:767\u201380.","journal-title":"Clin Pharmacokinet"},{"key":"1642_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104278","volume":"154","author":"K Dao","year":"2020","unstructured":"Dao K, Guidi M, Andr\u00e9 P, et al. Optimisation of vancomycin exposure in neonates based on the best level of evidence. Pharmacol Res. 2020;154:104278.","journal-title":"Pharmacol Res"},{"key":"1642_CR4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/2160763X12456843","volume":"1","author":"A Marsot","year":"2012","unstructured":"Marsot A, Vialet R, Boulamery A, et al. Vancomycin: predictive performance of a population pharmacokinetic model and optimal dose in neonates and young infants. Clin Pharmacol Drug Dev. 2012;1:144\u201351.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1642_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-024-01459-z","volume":"64","author":"M Albanell-Fern\u00e1ndez","year":"2025","unstructured":"Albanell-Fern\u00e1ndez M, Rodr\u00edguez-Reyes M, Bastida C, et al. A review of vancomycin, gentamicin, and amikacin population pharmacokinetic models in neonates and infants. Clin Pharmacokinet. 2025;64:1\u201325.","journal-title":"Clin Pharmacokinet"},{"key":"1642_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.pedneo.2021.11.010","volume":"63","author":"Q Chen","year":"2022","unstructured":"Chen Q, Wan J, Shen W, et al. Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: a retrospective study based on electronic medical records. Pediatr Neonatol. 2022;63:247\u201354.","journal-title":"Pediatr Neonatol"},{"key":"1642_CR7","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1093\/jac\/dkae374","volume":"79","author":"Y Gao","year":"2024","unstructured":"Gao Y, Wu T, Pu L, et al. Identification of vancomycin exposure target in neonates: how much is enough? J Antimicrob Chemother. 2024;79:3344\u201353.","journal-title":"J Antimicrob Chemother"},{"key":"1642_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106300","volume":"57","author":"Z Tang","year":"2021","unstructured":"Tang Z, Guan J, Li J, et al. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing. Int J Antimicrob Agents. 2021;57:106300.","journal-title":"Int J Antimicrob Agents"},{"key":"1642_CR9","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s10096-018-3277-8","volume":"37","author":"A Smits","year":"2018","unstructured":"Smits A, Pauwels S, Oyaert M, et al. Factors impacting unbound vancomycin concentrations in neonates and young infants. Eur J Clin Microbiol Infect Dis. 2018;37:1503\u201310.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1642_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.420","volume":"6","author":"JF Monteiro","year":"2018","unstructured":"Monteiro JF, Hahn SR, Gon\u00e7alves J, et al. Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations. Pharmacol Res Perspect. 2018;6:e00420.","journal-title":"Pharmacol Res Perspect"},{"key":"1642_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000001293","author":"KJ Downes","year":"2025","unstructured":"Downes KJ, Sharova A, Malone J, et al. Multiple model optimal sampling promotes accurate vancomycin area-under-the-curve estimation using a single sample in critically ill children. Ther Drug Monit. 2025. https:\/\/doi.org\/10.1097\/FTD.0000000000001293.","journal-title":"Ther Drug Monit"},{"key":"1642_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02042-17","author":"MN Neely","year":"2018","unstructured":"Neely MN, Kato L, Youn G, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.02042-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1642_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01293-17","author":"NA Finch","year":"2017","unstructured":"Finch NA, Zasowski EJ, Murray KP, et al. A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.01293-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1642_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/600877","volume":"49","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotscahfer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49:325\u20137.","journal-title":"Clin Infect Dis"},{"key":"1642_CR15","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1097\/INF.0b013e318299f75c","volume":"32","author":"A Frymoyer","year":"2013","unstructured":"Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections. Pediatr Infect Dis J. 2013;32:1077\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"1642_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/cpt.334","volume":"99","author":"D Mould","year":"2016","unstructured":"Mould D, D\u2019Haens G, Upton R. Clinical decision support tools: the evolution of a revolution. Clin Pharmacol Ther. 2016;99:405\u201318.","journal-title":"Clin Pharmacol Ther"},{"key":"1642_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115421","author":"IK Minichmayr","year":"2024","unstructured":"Minichmayr IK, Dreesen E, Centanni M, et al. Model-informed precision dosing: state of the art and future perspectives. Adv Drug Deliv Rev. 2024. https:\/\/doi.org\/10.1016\/j.addr.2024.115421.","journal-title":"Adv Drug Deliv Rev"},{"key":"1642_CR18","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/cpt.2202","volume":"109","author":"SG Wicha","year":"2021","unstructured":"Wicha SG, M\u00e4rtson AG, Nielsen EI, et al. From therapeutic drug monitoring to model\u2010informed precision dosing for antibiotics. Clin Pharmacol Ther. 2021;109:928\u201341.","journal-title":"Clin Pharmacol Ther"},{"key":"1642_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40262-025-01478-4","volume":"64","author":"A Duong","year":"2025","unstructured":"Duong A, Le Blanc J, Projean D, et al. Identifying the optimal sampling strategy for the Bayesian estimation of vancomycin AUC0\u201324 in adult hematologic cancer patients. Clin Pharmacokinet. 2025;64:297\u2013305.","journal-title":"Clin Pharmacokinet"},{"key":"1642_CR20","doi-asserted-by":"crossref","unstructured":"Dubovitskaya A, Buclin T, Schumacher M, et al. Tucuxi, an intelligent system for personalized medicine: from individualization of treatments to research databases and back. In: Proceedings of the 8th ACM international conference on bioinformatics, computational biology, and health informatics; 2017.","DOI":"10.1145\/3107411.3107439"},{"key":"1642_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.smhl.2025.100600","author":"Y Thoma","year":"2025","unstructured":"Thoma Y, Buclin T. TUCUXI-Core: an open source generic and efficient computing engine for model-informed precision dosing. Smart Health. 2025. https:\/\/doi.org\/10.1016\/j.smhl.2025.100600.","journal-title":"Smart Health"},{"key":"1642_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70077","author":"A Ravix","year":"2025","unstructured":"Ravix A, Cathignol AE, Buclin T, et al. Numerical verification of Tucuxi, a promising Bayesian adaptation tool for model\u2010informed precision dosing. CPT Pharmacomet Syst Pharmacol. 2025. https:\/\/doi.org\/10.1002\/psp4.70077.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1642_CR23","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1055\/s-2006-924458","volume":"66","author":"M Voigt","year":"2006","unstructured":"Voigt M, Fusch C, Olbertz D, et al. Analyse des Neugeborenenkollektivs der Bundesrepublik Deutschland. Geburtshilfe Frauenheilkd. 2006;66:956\u201370.","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"1642_CR24","unstructured":"Swiss society of paediatrics. Paediatric Growth Curves. [web site] 2011."},{"key":"1642_CR25","unstructured":"SwissMedicInfo. Vancomycin Sandoz\u00ae i.v. [web site] 11\/2023. https:\/\/www.swissmedicinfo.ch\/ViewMonographie. Accessed 13 Feb 2025."},{"key":"1642_CR26","unstructured":"Ainsworth S. Neonatal Formulary: drug use in pregnancy and the first year of life. Vancomycin. (seven edition); 2015;520\u20132."},{"key":"1642_CR27","unstructured":"SwissPedDose. Vancomycin (IV). General use (neonatology). [web site] 01\/14\/2025. https:\/\/db.swisspeddose.ch\/search\/?_search_en=vanco. Accessed 13 Feb 2025."},{"key":"1642_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16345","author":"M El Hassani","year":"2024","unstructured":"El Hassani M, Blouin M, Marsot A. A simulation study to assess the influence of population pharmacokinetic model selection on initial dosing recommendations of vancomycin in neonates. Br J Clin Pharmacol. 2024. https:\/\/doi.org\/10.1111\/bcp.16345.","journal-title":"Br J Clin Pharmacol"},{"key":"1642_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/psp4.12782","volume":"11","author":"DW Uster","year":"2022","unstructured":"Uster DW, Wicha SG. Optimized sampling to estimate vancomycin drug exposure: comparison of pharmacometric and equation\u2010based approaches in a simulation\u2010estimation study. CPT Pharmacomet Syst Pharmacol. 2022;11:711\u201320.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1642_CR30","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1093\/jac\/dkaa320","volume":"75","author":"RV Shingde","year":"2020","unstructured":"Shingde RV, Reuter SE, Graham GG, et al. Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure. J Antimicrob Chemother. 2020;75:3293\u2013302.","journal-title":"J Antimicrob Chemother"},{"key":"1642_CR31","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1111\/cts.13626","volume":"16","author":"K Oda","year":"2023","unstructured":"Oda K, Yamada T, Matsumoto K, et al. Model\u2010informed precision dosing of vancomycin for rapid achievement of target area under the concentration\u2010time curve: a simulation study. Clin Transl Sci. 2023;16:2265\u201375.","journal-title":"Clin Transl Sci"},{"key":"1642_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40262-022-01185-4","volume":"62","author":"JH Hughes","year":"2023","unstructured":"Hughes JH, Tong DMH, Faldasz JD, et al. Evaluation of neonatal and paediatric vancomycin pharmacokinetic models and the impact of maturation and serum creatinine covariates in a large multicentre data set. Clin Pharmacokinet. 2023;62:67\u201376.","journal-title":"Clin Pharmacokinet"},{"key":"1642_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00551","author":"A Frymoyer","year":"2020","unstructured":"Frymoyer A, Schwenk HT, Zorn Y, et al. Model-informed precision dosing of vancomycin in hospitalized children: implementation and adoption at an academic children\u2019s hospital. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.00551.","journal-title":"Front Pharmacol"},{"key":"1642_CR34","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s11096-018-0670-4","volume":"40","author":"JJB Seng","year":"2018","unstructured":"Seng JJB, Yong MHA, Peh ZX, et al. Appropriateness of vancomycin therapeutic drug monitoring and its outcomes among non-dialysis patients in a tertiary hospital\u00a0in Singapore. Int J Clin Pharm. 2018;40:977\u201381.","journal-title":"Int J Clin Pharm"},{"key":"1642_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071859","volume":"15","author":"P Del Valle-Moreno","year":"2023","unstructured":"Del Valle-Moreno P, Suarez-Casillas P, Mej\u00edas-Trueba M, et al. Model-informed precision dosing software tools for dosage regimen individualization: a scoping review. Pharmaceutics. 2023;15:1859.","journal-title":"Pharmaceutics"},{"key":"1642_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/jpids\/pix109","volume":"8","author":"A Frymoyer","year":"2019","unstructured":"Frymoyer A, Stockmann C, Hersh AL, et al. Individualized empiric vancomycin dosing in neonates using a model-based approach. J Pediatr Infect Dis Soc. 2019;8:97\u2013104.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"1642_CR37","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01591-23","author":"R Kalamees","year":"2024","unstructured":"Kalamees R, Soeorg H, Ilmoja M-L, et al. Prospective validation of a model-informed precision dosing tool for vancomycin treatment in neonates. Antimicrob Agents Chemother. 2024. https:\/\/doi.org\/10.1128\/aac.01591-23.","journal-title":"Antimicrob Agents Chemother"},{"key":"1642_CR38","doi-asserted-by":"crossref","unstructured":"Hughes DM, Goswami S, Keizer RJ, et al. Bayesian clinical decision support-guided versus clinician-guided vancomycin dosing in attainment of targeted pharmacokinetic parameters in a paediatric population. J Antimicrob Chemother. 2019;75;434\u20137.","DOI":"10.1093\/jac\/dkz444"},{"key":"1642_CR39","doi-asserted-by":"crossref","unstructured":"De Cock PA, Colman R, Amza A, et al. A multicentric, randomized, controlled clinical trial to study the impact of bedside model-informed precision dosing of vancomycin in critically ill children\u2014BENEFICIAL trial. Trials. 2024;25:669.","DOI":"10.21203\/rs.3.rs-3915082\/v1"},{"key":"1642_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S2352-4642(21)00305-9","volume":"6","author":"LF Hill","year":"2022","unstructured":"Hill LF, Clements MN, Turner MA, et al. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial. Lancet Child Adolesc Health. 2022;6:49\u201359.","journal-title":"Lancet Child Adolesc Health."},{"key":"1642_CR41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jcrc.2013.03.003","volume":"28","author":"BOM Claus","year":"2013","unstructured":"Claus BOM, Hoste EA, Colpaert K, et al. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care. 2013;28:695\u2013700.","journal-title":"J Crit Care"},{"key":"1642_CR42","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/FTD.0000000000001226","volume":"46","author":"M Blouin","year":"2024","unstructured":"Blouin M, M\u00e9tras M-\u00c9, El Hassani M, et al. Optimization of vancomycin initial dosing regimen in neonates using an externally evaluated population pharmacokinetic model. Ther Drug Monit. 2024;46:744\u201355.","journal-title":"Ther Drug Monit"},{"key":"1642_CR43","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/clinchem\/hvad036","volume":"69","author":"TA Nguyen","year":"2023","unstructured":"Nguyen TA, Kirubakaran R, Schultz HB, et al. Analytical and non-analytical variation may lead to inappropriate antimicrobial dosing in neonates: An in silico study. Clin Chem. 2023;69:637\u201348.","journal-title":"Clin Chem"},{"key":"1642_CR44","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/FTD.0000000000000904","volume":"43","author":"MD Kruizinga","year":"2021","unstructured":"Kruizinga MD, Stuurman FE, Driessen GJA, et al. Theoretical performance of nonlinear mixed-effect models incorporating saliva as an alternative sampling matrix for therapeutic drug monitoring in pediatrics: A simulation study. Ther Drug Monit. 2021;43:546\u201354.","journal-title":"Ther Drug Monit"},{"key":"1642_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01128-z","author":"B-F Yao","year":"2022","unstructured":"Yao B-F, Wu Y-E, Tang B-H, et al. Predictive performance of pharmacokinetic model-based virtual trials of vancomycin in neonates: mathematics matches clinical observation. Clin Pharmacokinet. 2022. https:\/\/doi.org\/10.1007\/s40262-022-01128-z.","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01642-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01642-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01642-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:07:51Z","timestamp":1781622471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01642-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1642"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01642-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflict of interest\/competing interests\n                      Thierry Buclin is an Editorial Board member of\n                      Clinical Pharmacokinetics\n                      . Thierry Buclin was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. The other authors have nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"No data were used in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The MIPD software used for this project is openly available on GitHub at\n                      \n                      . The Python code required to run the simulations and analyses is available upon request from the corresponding authors.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: AR, YT, AC, PT, CM, EG, TB, CC, KD, and MG; formal analysis: AR, YT, KD, and MG; methodology: AR, YT, AC, TB, CC, KD, and MG; supervision: KD and MG; writing\u2014original draft: AR and KD; writing\u2014review and editing: AR, YT, AC, PT, CM, EG, TB, CC, KD, and MG. All authors have read and agreed to the published version of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}